Concepedia
Statistics
Publications
12
Citations
1.2K
H-Index
11
Active since
2009
Affiliations
Agios Pharmaceuticals (United States)(Current)
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim (United States)
Kettering University
Raj Nagaraja is an author at Agios Pharmaceuticals (United States) specializing in molecular oncology, pharmacology, and medicine.
Publications per year
2009–2021
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 458 citations · Full text
Medicine, Oncology, Pharmacology +17
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
Peter Kalev, Marc L. Hyer, Zenon Konteatis et al. · Cancer Cell · 2021 · 234 citations
Life Sciences, Molecular Biology, Oncology +7
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon Konteatis, Erin Artin, Brandon Nicolay et al. · ACS Medicinal Chemistry Letters · 2020 · 186 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +16
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion
Zenon Konteatis, Jeremy Travins, Katya Marjon et al. · Journal of Medicinal Chemistry · 2021 · 97 citations · Full text
Pharmacy, Oncology, Pharmacology +16
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara et al. · Journal of Clinical Investigation · 2018 · 79 citations · Full text
Medicine, Molecular Biology, Oncology +17
1–5 of 12